Auro-Abacavir/Lamivudine 600mg/300 mg TABLET
PDF Leaflet Revision Date: 11 April 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of HIV in adults and adolescents from 12 years.
Dosage (summary)
One tablet once daily.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- Trimethoprim increases lamivudine exposure
- Not recommended with zalcitabine
Contraindications
- Hypersensitivity to abacavir or lamivudine
- Moderate to severe liver impairment
- Weight < 40 kg
- Children < 12 years
Common side effects
- Hypersensitivity reactions
- Nausea
- Diarrhea
- Fatigue
- Rash
Counselling Points
- Inform about hypersensitivity risks
- Do not restart after hypersensitivity
- Regular monitoring of liver function
Serious warnings
- Risk of hypersensitivity reactions
- Lactic acidosis
- Severe hepatotoxicity
Important Disclaimer
The Auro-Abacavir/Lamivudine 600mg/300 mg TABLET professional information leaflet below is the property of Aurobindo Pharma and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
